Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Director | July 01, 2024 | July 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date July 01, 2024 · Filed July 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 117,455 |
Reported balance
After 2024-07-01 transaction · row 1
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 33,784 · Balance 117,455 F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Jul 2, 2024 22:47 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 33,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026088 · ownership.xml · nonDerivative · entry 1 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,455 F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024. Read SEC document |
| June 12, 2024 Filed Jun 15, 2024 00:45 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 8,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-023996 · ownership.xml · nonDerivative · entry 1 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,671 F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest immediately. Read SEC document |
| January 01, 2024 Filed Jan 25, 2024 01:52 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 12,668 | $1.48 | $18,748.64 |
DisclosureSEC source: 0001493152-24-003692 · ownership.xml · nonDerivative · entry 2 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,375 F2 · shares: Represents a grant from the Issuer to Mr. Knight of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year Read SEC document |
| October 01, 2023 Filed Jan 25, 2024 01:52 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 11,867 | $1.58 | $18,749.86 |
DisclosureSEC source: 0001493152-24-003692 · ownership.xml · nonDerivative · entry 1 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,707 F1 · shares: Represents a grant from the Issuer to Mr. Knight of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document |
| July 01, 2023 Filed Jul 6, 2023 20:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 10,245 | $1.83 | $18,748.35 |
DisclosureSEC source: 0001493152-23-023816 · ownership.xml · nonDerivative · entry 3 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,840 F3 · shares: Represents a grant from the Issuer to Mr. Knight of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document |
| April 15, 2023 Filed Jul 6, 2023 20:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 9,920 | $1.89 | $18,748.80 |
DisclosureSEC source: 0001493152-23-023816 · ownership.xml · nonDerivative · entry 2 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,595 F2 · shares: Represents a grant from the Issuer to Mr. Knight of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Mr. Knight continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document |
| January 01, 2023 Filed Jul 6, 2023 20:15 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 8,227 | $2.28 | $18,757.56 |
DisclosureSEC source: 0001493152-23-023816 · ownership.xml · nonDerivative · entry 1 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,675 F1 · shares: Represents a grant from bioAffinity Technologies, Inc. (the "Issuer") to Mr. Knight of 8,227 restricted shares of common stock, par value $0.007 (the "Common Stock"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document |
| August 31, 2022 Filed Dec 5, 2022 21:12 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | PurchaseNon-tradeable Warrants (right to buy) · Derivative | 8,163 | Not disclosed Strike: $7.66 | Not disclosed |
DisclosureSEC source: 0001493152-22-034466 · ownership.xml · derivative · entry 3 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,163 Underlying: Common Stock · 8,163 shares Expires 2027-08-31 F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). F2 · derivative.exercise_price: The reported securities are included within 8,163 Units purchased by Mr. Knight for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. F2 · price: The reported securities are included within 8,163 Units purchased by Mr. Knight for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. Read SEC document |
| August 31, 2022 Filed Dec 5, 2022 21:12 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | PurchaseWarrants (right to buy) · Derivative | 8,163 | Not disclosed Strike: $7.35 | Not disclosed |
DisclosureSEC source: 0001493152-22-034466 · ownership.xml · derivative · entry 2 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,163 Underlying: Common Stock · 8,163 shares Expires 2027-08-31 F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). F2 · derivative.exercise_price: The reported securities are included within 8,163 Units purchased by Mr. Knight for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. F2 · price: The reported securities are included within 8,163 Units purchased by Mr. Knight for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. Read SEC document |
| August 31, 2022 Filed Dec 5, 2022 21:12 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | PurchaseCommon Stock, par value $0.007 | 8,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-22-034466 · ownership.xml · nonDerivative · entry 1 KNIGHT PETER S · CIK 0001189792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,448 F1 · security: The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"). F2 · price: The reported securities are included within 8,163 Units purchased by Mr. Knight for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one five-year tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.